IPI is deploying the LSA instrument because it is the only instrument on the market that can deliver the high-throughput kinetics and epitope binning data critical to making informed biotherapeutic candidate selections.
SALT LAKE CITY (PRWEB) April 04, 2018
Carterra™ Inc., an innovative label-free biosensor company, and Institute for Protein Innovation (IPI) announced today that IPI has purchased a Carterra LSA™, a fully automated, label-free, high-throughput monoclonal antibody (mAb) characterization instrument. Funding for the purchase of the LSA instrument was provided through a Massachusetts Life Sciences Center Capital Program Grant awarded to IPI.
Carterra’s LSA instrument is unique in that it provides the mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, thereby expanding IP coverage for research groups.
“IPI is committed to operating at the forefront of innovative protein research. The enhanced functionalities of Carterra’s LSA instrument complement our existing high-throughput protein production and antibody discovery pipelines and will accelerate fulfillment of our institutional mandate to produce open-source antibodies against all human extracellular and secreted proteins,” said James Love, COO, IPI.
“We are very excited that IPI is leading the way with the first LSA instrument purchase by a research institute,” said Josh Eckman, CEO, Carterra. “Along with large pharmaceutical and leading biotech companies, IPI is deploying the LSA instrument because it is the only instrument on the market that can deliver the high-throughput kinetics and epitope binning data critical to making informed biotherapeutic candidate selections.”
IPI will utilize the LSA instrument for rapid biophysical characterization of antibodies isolated from their synthetic yeast display library platform. IPI will also leverage the instrument’s unique capabilities to process antibodies against a wide panel of antigens to validate specificity and to select for species cross-reactivity. These are key metrics in generating open-source antibodies with broad usefulness to the scientific community engaged in basic research and drug discovery.
For further information, please contact:
About Carterra Inc.
Carterra™ is the leading provider of innovative Surface Plasmon Resonance (SPR) based technology for monoclonal antibody (mAb) discovery and characterization. Carterra’s high throughput LSA™ Array SPR instrument combines patented microfluidics technology with real-time SPR, enabling single unattended runs for: >1,000 kinetic interactions; 384x384 epitope binning; >1,000 quantitation measurements; 384 epitope mapping. Combined with Carterra’s unique data analysis and visualization software, the platform delivers the highest throughput and data quality available for mAb characterization, while using minimal sample.
About Institute for Protein Innovation (IPI).
IPI is a non-profit research organization whose mission is to foster innovation in protein research, train the next generation of innovators and entrepreneurs in protein science, forge new ties between academic and industry investigators, and bridge the missing link between genomics and therapeutics. IPI has built a high-throughput antibody discovery platform for developing open-source antibodies targeting the entire human extracellular proteome. This resource will produce critical tools, lead therapeutics, and technologies that empower academic and industry scientists, catalyze entrepreneurship, and accelerate drug discovery.